Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series

• Published in: Future oncology (London, England) Vol. 13; no. 11s; pp. 25 - 33
• Main Authors: Morritti, Maria, Iodice, Giuseppe, Melaccio, Assunta, D'Onofrio, Loretta, Bergnolo, Paola, Boglione, Antonella, Comandone, Alessandro, Molinaro, Peppina, Garigliano, Danula
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-05-2017
• Subjects: Adult; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - drug therapy; Cancer therapies; Chemotherapy; Cytotoxicity; Endocrine therapy; eribulin; Female; Furans - administration & dosage; Furans - adverse effects; Furans - therapeutic use; Humans; Immunotherapy; Ketones - administration & dosage; Ketones - adverse effects; Ketones - therapeutic use; line of treatment; Metastasis; metastatic breast cancer; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oncology; Patients; Positron-Emission Tomography; progression-free survival; Radiation therapy; Retreatment; Systematic review; Tomography, X-Ray Computed; Treatment Outcome; Womens health; chemotherapy; progression-free survival; eribulin; metastatic breast cancer; line of treatment
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2016-0529

During the last decades, much effort has been made to develop and test treatments for advanced/metastatic breast cancer (MBC) able to prolong survival and improve patients' quality of life. In this regard, eribulin represents one of the most recent and interesting discoveries. This tubulin-targeting chemotherapy demonstrated a survival benefit in MBC women who progressed after at least two prior lines of chemotherapy for the treatment of metastatic disease (prior therapies should have included an anthracycline and a taxane, in either adjuvant or metastatic setting). Here, we described five cases of heavily pretreated MBC patients who experienced long-lasting control of disease with eribulin.